The Augerton Digest

The news, in minutes.

The FDA declined to approve lung cancer drug ivonescimab

Published

The FDA declined to approve ivonescimab, a lung cancer drug first developed by China’s Akeso and being developed outside China by Summit Therapeutics, after a late-stage trial showed it delayed disease progression but did not demonstrate a statistically significant overall-survival benefit. The agency said the progression benefit alone did not establish a positive benefit-risk balance for approval.

Get The Augerton Digest by email.

We'll never sell your email. Privacy

Bloomberg said Summit sought authorization for the drug to treat a narrow group of patients with advanced non-small cell lung cancer who had previously received EGFR-targeting drugs. Reuters reported that, when combined with chemotherapy, ivonescimab reduced the risk of progression or death by 48% compared with chemotherapy alone.

Summit has argued that longer follow-up supports the treatment, citing revised data showing lower death rates among Western and Asian patient subgroups, The News International reported.

Also in the Afternoon Edition

Reporting behind this story

How we verify summaries

In these editions

Get The Augerton Digest by email

Free. Choose your editions. Unsubscribe anytime.

Editions

We'll never sell or share your email. Privacy